Clinical Impact of the Revised 2019 CLSI Levofloxacin Breakpoints in Patients with Enterobacterales Bacteremia-Reference-Cited by-同舟云学术

Clinical Impact of the Revised 2019 CLSI Levofloxacin Breakpoints in Patients with Enterobacterales Bacteremia

Published:2021-05-18 Issue:6 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Huang Ho-Yin¹²,Wang Chu-Feng³,Lu Po-Liang⁴⁵,Tseng Sung-Pin⁶,Wang Ya-Ling¹,Chen Tun-Chieh⁴⁷,Chang Ko⁴⁸,Tu Hung-Pin⁹,Lin Shang-Yi³⁴⁵¹⁰^ORCID

Affiliation:

1. Department of Pharmacy, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

2. School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan

3. Department of Laboratory Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

4. Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

5. College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

6. Department of Medical Laboratory Science and Biotechnology, College of Health Sciences, Kaohsiung Medical University, Kaohsiung, Taiwan

7. Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

8. Department of Internal Medicine, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

9. Department of Public Health and Environmental Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

10. Graduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

Abstract

The Clinical and Laboratory Standards Institute (CLSI) revised the fluoroquinolone MIC breakpoints for Enterobacterales in 2019, based on pharmacokinetic/pharmacodynamic analyses. However, clinical evidence supporting these breakpoint revisions is limited.

Funder

Kaohsiung Medical University Chung-Ho Memorial Hospital

Ministry of Science and Technology, Taiwan

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00074-21

Reference34 articles.

1. Levofloxacin

2. Mechanisms of Action of Antimicrobials: Focus on Fluoroquinolones

3. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success

4. Clinical and Laboratory Standards Institute. 2019. Performance standards for antimicrobial susceptibility testing. CLSI supplement M100, 29th ed. Clinical and Laboratory Standards Institute, Wayne, PA.

5. Clinical and Laboratory Standards Institute. 2019. Fluoroquinolone breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa. CLSI rationale document MR02. Clinical and Laboratory Standards Institute, Wayne, PA.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Health Threat from Farm to Fork: Shiga Toxin-Producing Escherichia coli Co-Harboring blaNDM-1 and mcr-1 in Various Sources of the Food Supply Chain;Pathogens;2024-08-06

2. Development of Nitroreductase‐Activatable Fluoroquinolone Prodrugs Exhibiting Attenuated Magnesium Ion Binding;Helvetica Chimica Acta;2023-09-13

3. Correlation of Vitek 2 and Agar dilution for levofloxacin susceptibility testing and clinical outcomes of Enterobacterales bacteremia with 2019 CLSI breakpoints;Diagnostic Microbiology and Infectious Disease;2022-12

4. Significant Publications on Infectious Diseases Pharmacotherapy in 2021;Journal of Pharmacy Practice;2022-09-19

5. Clinical effectiveness of beta-lactams versus fluoroquinolones as empirical therapy in patients with diabetes mellitus hospitalized for urinary tract infections: A retrospective cohort study;PLOS ONE;2022-03-31